When fear won’t let go: What a human-produced cannabinoid means for trauma reduction

Why do some people seem to carry fear with them, long after the danger has passed? Why does something that is, to some, seemingly benign (a noise, a whiff of an unexpected scent, a shadow or flickering light), trigger a similar feeling of dread or the fight-or-flight response to others, who have a long-held, deeply ingrained trauma?

According to new cross-species research, part of the answer may lie in a tiny molecule human brains produce - one of our endogenous cannabinoids...

2-AG or 2-arachidonoylglycerol is an endocannabinoid, and part of the body’s endocannabinoid system, a complex network that shapes how we process stress, modulate fear, and return to emotional baseline (along with an astounding number of other essential functions, from appetite and pain to memory and immune regulation). 

And when 2-AG is in short supply, fear appears to spill over. The boundaries between what’s truly dangerous and what isn’t can start to blur, or at least that’s what this newly released research paper strongly suggests.

This study, published in May 2025 and reported on by New Atlas, combined behavioural testing, brain imaging, and molecular analysis in both humans and mice. The goal was to investigate how 2-AG levels influence fear generalisation.

What is fear generalisation?

Fear generalisation, put simply, is the tendency to apply fear learned in one situation to others that are similar but not as threatening, or not dangerous at all. This is an issue faced by many people with PTSD, and so understanding what regulates that process, and what helps the brain tell the difference, could be key to reducing the impact of trauma-related conditions.

The findings were in equal parts fascinating and, surprising.

A molecule that distinguishes threat from safety

In total, 101 participants took part in the study, undergoing fear conditioning, startle testing, brain imaging, and blood sampling to measure their endocannabinoid levels. Some had known risk factors for psychiatric vulnerability, such as childhood trauma or substance use, while others had no such history.

Across the full sample, the researchers found that lower levels of the endocannabinoid 2-AG were linked to greater fear generalisation.

Participants with lower 2-AG were more likely to respond to neutral cues as if they were threatening. They also showed weaker connectivity between the prefrontal cortex and amygdala, a circuit critical for regulating fear, and reported more difficulty managing their emotions.

In mice, artificially lowering 2-AG had a striking effect. 

The animals began to freeze in response to harmless tones, unfamiliar settings, and subtle changes in their environment. At the neural level, fear-related brain circuits became less selective. Instead of firing only in response to a threat, they activated broadly, even when the stimulus should have felt safe.

While the study wasn’t limited to people with PTSD, these findings are especially relevant to the condition, because fear generalisation is a hallmark symptom of PTSD. 

Typically, trauma survivors start responding not just to the original trigger, but they can also respond to anything that faintly resembles it. The authors don’t claim that people with PTSD universally have low 2-AG. But the data suggest that lower 2-AG levels may impair the brain’s ability to distinguish safety from danger, and that this could contribute to PTSD-like patterns of overgeneralised fear.

In that sense, 2-AG isn’t a diagnostic marker, it’s more a regulatory molecule, one that seems to act as a buffer against emotional spillover. 

When it’s in short supply, the brain becomes more reactive and more likely to treat safe cues as threats.

Trauma, PTSD, and the blurry edges of fear

Researchers and doctors have long known that post-traumatic stress disorder (PTSD) involves an overactive fear response, but they haven’t always understood what drives that overactivity on a molecular level. This study suggests that 2-AG acts as a kind of emotional filter, sharpening the line between what’s threatening and what isn’t.

Without enough of it, the fear response becomes more generalised. And once it generalises, it becomes harder to contain.

This may help explain why that while some people go on to develop PTSD after trauma, others don’t. It could also open the door to new treatment targets. Ones that involve modulating 2-AG levels, either directly, or, through broader support of the endocannabinoid system.

It’s worth noting that while cannabis does engage this system, this isn’t an argument for self-medicating with THC. If anything, the data suggest a need for precision. 

That said, medical cannabis for PTSD is an area of growing clinical interest, and at Releaf, we’re already supporting UK patients who are navigating trauma and its after-effects. This research mirrors what many of our patients report, which is greater emotional stability with the right support

Moving from correlation to care

Of course, questions remain. 

Blood levels of 2-AG don’t necessarily reflect what’s happening at the synapse. The prefrontal cortex and amygdala are complex regions, and connectivity in a resting-state scan only tells us so much. There were no longitudinal data to show whether these patterns persist or predict long-term outcomes.

The most promising detail? 

2-AG deficiency seems to be a biomarker for certain mental health issues, but more research is needed to fully confirm these findings. 

That means in the future, we might not need to wait until symptoms fully emerge to know who’s at risk. We could measure it. Track it. And ultimately, support the system before it breaks.

In the meantime, studies like this remind us that trauma isn't a failure of character. It's a physiological state. It’s a sign of the brain trying to protect itself but also shaped by stress, and sometimes, stripped of healthy balance. If encouraging 2-AG production, or supporting the endocannabinoid system through medical cannabis treatment, helps restore that balance even that little bit, it deserves further attention and study.

If you’re living with anxiety, depression, or PTSD symptoms and are interested in complementary treatment options when conventional routes have failed, medical cannabis may be one to consider. 

At Releaf, we offer access to personalised care through our world-class clinical team, with experience supporting patients through medical cannabis treatment for a range of mental health conditions. 

You can find out if treatment might be suitable for you by using our free medical cannabis eligibility checker. It’s totally confidential and takes less than 20 seconds to complete.